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Abstract
Background and Objectives—Gender-specific factors associated with stimulant abstinence 
severity were examined in a stimulant abusing or dependent residential treatment sample (N=302).
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Method—Bivariate statistics tested gender differences in stimulant abstinence symptoms, 
measured by participant-reported experiences of early withdrawal. Multivariate linear regression 
examined gender and other predictors of stimulant abstinence symptom severity.
Results—Women compared to men reported greater stimulant abstinence symptom severity. 
Anxiety disorders and individual anxiety-related abstinence symptoms accounted for this 
difference. African American race/ethnicity was predictive of lower stimulant abstinence severity.
Discussion and Conclusions—Women were more sensitive to anxiety-related stimulant 
withdrawal symptoms.
Scientific Significance—Clinics that address anxiety-related abstinence symptoms, which 
more commonly occur in women, may improve treatment outcome.
Keywords
gender; stimulant abstinence severity; early withdrawal symptoms; anxiety
BACKGROUND AND OBJECTIVES
Current U.S. population surveys indicate more general drug use and higher rates of illicit 
drug dependence for men than women.1 However, male and female patterns of use and 
disorders differ by the specific drug used. Combined annual data from the most recent 
National Survey on Drug Use and Health showed no significant gender difference in the 
abuse of cocaine.2 Studies suggest that female users exceed males on the severity of 
dependence regardless of the stimulant used,3,4 and addiction severity at treatment entry for 
drug abuse has been linked to poorer outcomes in clinical samples.5
Specifically for stimulant abuse, more severe abstinence symptoms have been associated 
with early treatment termination and greater problems on the Addiction Severity Index drug 
use subscale.6,7 Stimulant abstinence symptoms are signs of early withdrawal and include 
sleep and eating disturbances, anxiety, and depression.7 The relationship of gender to 
stimulant abstinence symptoms and the specific factors associated with stimulant abstinence 
symptom severity are not well described. This secondary analysis examined gender 
characteristics among baseline participants in a multisite randomized clinical trial testing the 
addition of vigorous exercise compared to health education as a treatment strategy for 
stimulant abuse or dependence. Our central aim was to test gender differences in stimulant 
abstinence symptom severity, as well as the demographic, drug use, and psychiatric factors 
associated with more severe stimulant abstinence symptoms.
METHODS
Participants
Participants (women n = 121 and men n = 181) were from the Stimulant Reduction 
Intervention using Dose Exercise (STRIDE) trial, a National Institute on Drug Abuse 
Clinical Trials Network study (CTN-0037). Full details about the protocol are described 
elsewhere.8 Briefly, recruitment occurred during residential treatment in nine geographically 
diverse community treatment programs that had a 21- to 30-day residential length of stay 
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and post-residential outpatient services. Eligible participants reported illicit stimulant drug 
use (e.g., cocaine, methamphetamine, or amphetamine) in the 30 days prior to residential 
treatment program (RTP) entry and received medical clearance for exercise. Individuals 
with an opioid dependence diagnosis, general medical conditions that contraindicated 
exercise, and those with psychosis or other psychiatric conditions that posed a potential 
safety risk were excluded. Participants provided informed consent.
Measures
All measures utilized for the STRIDE trial were described in Trivedi et al., 2011.8 
Demographic variables included age, race/ethnicity, level of education, employment status, 
and marital status.
The Addiction Severity Index-Lite (ASI-Lite) provided lifetime measures of years of 
primary stimulant use (cocaine, amphetamine, or methamphetamine) and assessed problems 
associated with drug use in seven domains: medical, employment, alcohol, drug use, legal, 
family/social, and psychiatric. The Timeline Followback (TLFB) measured days of 
stimulant use in the 30 days prior to RTP entry.
The Composite International Diagnostic Interview (CIDI) was used to determine stimulant 
use disorders (categorized here as: cocaine only, cocaine and other stimulants, or other 
stimulants--not cocaine--only), as well as other substance use disorders using Diagnostic 
and Statistical Manual-IV (DSM-IV) criteria. The Fagerstrom Test for Nicotine Dependence 
(FTND) measured current nicotine dependence intensity.
The Mini International Neuropsychiatric Interview (MINI) measured DSM-IV psychiatric 
disorders, including major depression, dysthymia, mania, post-traumatic stress disorder 
(PTSD), panic disorder, social phobia, and obsessive compulsive disorder (OCD).
The Stimulant Selective Severity Assessment (SSSA; based on the Cocaine Selective 
Severity Assessment (CSSA)) measured self-reported stimulant abstinence symptom severity 
for the past 24 hours.7 The SSSA covered cocaine, methamphetamine, and other stimulants. 
Domains included carbohydrate craving, mood, appetite, sleep, energy, and pulse rate. 
Participants indicated the frequency or intensity of their withdrawal experiences for 16 
individual symptoms on a scale of 0 to 7, including, for example, anxiety (i.e., 0 usually 
doesn't feel anxious; 3-4 anxious half the time; and 7 anxious all the time) and irritability 
(i.e., 0 most things are not irritating; 3-4 many things are irritating; and 7 mostly everything 
is irritating or upsetting). The CSSA stimulant craving items were not included in this SSSA 
measure.
Analysis
Bivariate tests for gender comparisons on sample characteristics were conducted using chi-
square and t tests, for categorical and continuous variables, respectively. A multivariate 
linear regression model tested the relationship of gender to stimulant abstinence symptom 
severity while controlling for other variables. Gender and variables found to be significant 
(p < .05) on bivariate tests were entered into the regression model simultaneously. ASI 
subscales were not included because of the overlap with other more informative variables 
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(e.g., the psychiatric problems subscale versus specific psychiatric diagnoses). For the 
modelled days of cocaine and methamphetamine use variables, we set days of use for non-
users to zero. Non-users were participants who responded ‘no’ to screening questions for 
any past-30 day cocaine or methamphetamine use. Diagnostics showed that normality and 
other standard assumptions for linear regression were met.
To further characterize the relationship between gender and stimulant abstinence symptom 
severity, two post hoc analyses were conducted. First, one variable at a time was removed 
from the linear regression model to examine the change in the relationship between gender 
and abstinence symptom severity. We removed comorbid psychiatric diagnosis variables 
with the smallest p-values. Additionally, t tests were conducted for gender and each 
individual abstinence symptom item.
RESULTS
Gender characteristics
On demographic variables, women were younger than men, M=35.67 (SD=9.9) versus 
M=41.17 (SD=10.8) years, and more likely to be Hispanic, 17.36% versus 5.52%, p-values 
< .001. Men were more likely to have a high school degree or more education (86.19% 
versus 74.38%, p=.023) and to be employed (39.23% versus 19.83%) and African American 
(51.93% versus 29.75%), p-values < .001.
Table 1 shows gender comparisons on measures of stimulant drug use, drug use problems, 
and comorbid drug use and psychiatric disorders. Men reported more years using stimulants 
as their primary drug. Women reported higher median cocaine and methamphetamine use 
days prior to RTP entry, and were more likely to report dual stimulant use disorders (cocaine 
use disorder plus another non-cocaine stimulant use disorder). Most men met the diagnosis 
for a cocaine use disorder only. Women had higher ASI subscale scores on employment, 
family/social, and psychiatric problems, while men had higher scores for alcohol problems. 
Men were also more likely to be diagnosed with alcohol dependence as well as marijuana 
dependence, and had greater nicotine dependence intensity. Women had a higher prevalence 
of current manic episode, panic disorder, and OCD diagnoses.
Stimulant abstinence symptom severity
On the SSSA, women reported greater stimulant abstinence symptom severity compared to 
men (Table 1). In the multivariate model, gender was no longer associated with abstinence 
symptom severity, p-value > .05. Model results are presented in Table 2. African American 
race/ethnicity was associated with lower abstinence symptom severity than non-African 
Americans after controlling for other variables in the model. Other modelled variables were 
non-significant; however, after two variables were removed from the model, i.e., 1) panic 
disorder and 2) OCD diagnoses, gender was associated with a higher stimulant abstinence 
severity score compared to men. Post hoc tests also identified higher scores for women on 
four individual abstinence symptoms, including anxiety (men: M=1.02, SD=1.7; women: 
M=1.74, SD=2.1, p=.001), tension (men: M=0.72, SD=1.5; women: M=1.09, SD=1.8, p=.
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047), attention (men: M=0.62, SD=1.4; women: M=1.12, SD=1.9, p=.008), and irritability 
(men: M=0.80, SD=1.4; women: M=1.55, SD=2.1, p<.001).
DISCUSSION AND CONCLUSIONS
We identified differences between men and women on measures of stimulant use and 
associated disorders. Women were more likely to report dual stimulant use disorders (i.e., 
cocaine and other stimulant use disorders), while most men met diagnosis for a cocaine use 
disorder only. These dual stimulant diagnoses corresponded with both more 
methamphetamine use days and more cocaine use days for women than men. Preclinical and 
clinical studies provide some evidence to indicate that women, via increased estrogen levels, 
are more vulnerable to the reinforcing effects of stimulant drugs.9
Women reported greater drug use problems in employment, family/social, and psychiatric 
domains compared to men. Men reported greater problems related to alcohol and were more 
likely to have an alcohol dependence diagnosis. This is consistent with other studies 
involving stimulant abusers, with women reporting more employment and economic issues 
and men more alcohol problems.10,11 Women in treatment also report significantly greater 
depressive symptomatology and a history of abuse and violence in their lives,10,5 although 
in the current study, major depression, dysthymia, and PTSD were not significantly different 
in men and women.
We found greater stimulant abstinence symptom severity in women compared to men. More 
severe early withdrawal symptoms appeared to be positively associated with anxiety-related 
symptoms (e.g., anxiety, tension, difficulty concentrating, and irritability), and panic 
disorder and OCD diagnoses appeared to account for the association between gender and 
stimulant abstinence symptom severity. Being African American was negatively associated 
with stimulant abstinence symptom severity. African Americans in the STRIDE sample, 
relative to other racial/ethnic groups, were majority male, reported better mental health 
status, and had low psychiatric comorbidity,12 which may help describe our findings here. 
Women may be more sensitive to the anxiety-related stimulant withdrawal symptoms. 
STRIDE women compared to men reported higher rates of anxiety-related disorders (i.e., 
panic disorder and obsessive compulsive disorder). Greater psychological severity in women 
is associated with poorer treatment retention and outcomes.5 Individuals who remain 
anxious during treatment may be at greater risk for using substances to reduce anxiety 
symptoms.13
There were some limitations to this study, including the retrospective assessment of drug 
use, drug use problems, and drug and psychiatric disorders. Self-report measures may be 
subject to recall bias (e.g., years of primary stimulant use), although most time periods 
assessed were relatively short (e.g., 24 hours and past 30 days for the SSSA and TLFB, 
respectively). The generalizability of our findings may be limited by the trial's sampling 
criteria. In particular, eligible participants agreed to participate in a clinical trial and were 
medically cleared and willing to exercise.
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SCIENTIFIC SIGNIFICANCE
Addiction severity at treatment entry is associated with treatment retention and abstinence 
outcomes. The CSSA is one measure of stimulant abstinence severity that has been shown to 
predict attrition from treatment,6 and could be used by clinic staff during the admissions 
process to identify and target stimulant abusing patients with greater risk for poor treatment 
outcomes. It is a brief self-administered measure, which potentially makes it well adaptable 
to a clinical setting. It could also be an effective tool for identifying specific symptoms (e.g., 
anxiety, tension, and irritability) to discuss with patients in treatment sessions. This study 
emphasized anxiety-related withdrawal experiences as salient topics for clinicians to address 
in treatment to reduce stimulant abstinence symptoms and potentially the risk for relapse to 
substance use. Mood and anxiety disorders are more prevalent in women and non-Hispanic 
whites.14 There are mixed findings related to gender and treatment retention,5 but women 
who complete stimulant treatment are reported to have similar or better outcomes than 
men.15 Future prospective studies could help clarify the relationships we identified between 
gender, race/ethnicity, stimulant abstinence symptom severity, and associated anxiety-
related factors.
Acknowledgements
The research reported in this publication was supported by the National Institute on Drug Abuse, Rockville, MD of 
the National Institutes of Health under award number U10DA020024 (PI: Trivedi). The content and writing are 
solely the responsibility of the authors and does not necessarily represent the official views of the National 
Institutes of Health. This paper was originally presented as a poster at the 2014 Society for Social Work and 
Research annual meeting.
REFERENCES
1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National 
Survey on Drug Use and Health: Summary of National Findings. Vol 1. NSDUH Series H-46, HHS 
Pub No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration; Rockville, 
MD: 2013. 
2. Cotto JH, Davis E, Dowling GJ, Elcano JC, Staton AB, Weiss SRB. Gender effects on drug use, 
abuse, and dependence: A special analysis of results from the National Survey on Drug Use and 
Health. Gender Medicine. 2010; 7(5):402–413. [PubMed: 21056867] 
3. Lejuez CW, Bornovalova MA, Reynolds EK, Daughters SB, Curtin JJ. Risk factors in the 
relationship between gender and crack/cocaine. Exp. Clin. Psychopharmacol. 2007; 15(2):165–175. 
[PubMed: 17469940] 
4. Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK. Heterogeneity of Stimulant 
Dependence: A National Drug Abuse Treatment Clinical Trials Network Study. American Journal 
on Addictions. 2009; 18(3):206–218. [PubMed: 19340639] 
5. Greenfield SF, Brooks AJ, Gordon SM, et al. Substance abuse treatment entry, retention, and 
outcome in women: a review of the literature. Drug Alcohol Depend. 2007; 86(1):1–21. [PubMed: 
16759822] 
6. Kampman KM, Alterman AI, Volpicelli JR, et al. Cocaine withdrawal symptoms and initial urine 
toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol 
Addict Behav. 2001; 15(1):52–59. [PubMed: 11255939] 
7. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the Cocaine Selective 
Severity Assessment. Addict Behav. 1998; 23(4):449–461. [PubMed: 9698974] 
8. Trivedi MH, Greer TL, Grannemann BD, Church TS, Somoza E, Blair SN, et al. Stimulant 
Reduction Intervention using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a 
randomized controlled trial. Trials. 2011; 12(15)
Chartier et al. Page 6
Am J Addict. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
9. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North 
Am. 2010; 33(2):339–355. [PubMed: 20385341] 
10. Cohen JB, Greenberg R, Uri J, Halpin M, Zweben JE. Women with methamphetamine 
dependence: research on etiology and treatment. Journal of psychoactive drugs. 2007; (Suppl 4):
347–351. [PubMed: 18284101] 
11. Najavits LM, Lester KM. Gender differences in cocaine dependence. Drug Alcohol Depend. 2008; 
97(1-2):190–194. [PubMed: 18571340] 
12. Sanchez K, Chartier K, Greer T, Walker R, Carmody T, Rethorst C, Ring K, dela Cruz A, Trivedi 
M. Comorbidities and Race/Ethnicity among Adults with Stimulant Use Disorders in Residential 
Treatment. J Ethn Subst Abuse. in press. 
13. Wolitzky-Taylor K, Operskalski JT, Ries R, Craske MG, Roy-Byrne P. Understanding and treating 
comorbid anxiety disorders in substance users: review and future directions. J Addict Med. 2011; 
5(4):233–247. [PubMed: 22042216] 
14. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and 
comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. 
Archives of general psychiatry. Jun; 2005 62(6):617–627. [PubMed: 15939839] 
15. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend 
Med. 2008; 5(1):24–35. [PubMed: 18420163] 
Chartier et al. Page 7
Am J Addict. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Chartier et al. Page 8
Table 1
Sample Characteristics and Stimulant Abstinence Symptom Severity by Gender
Baseline variables Total M (SD) or % N = 
302
Male M (SD) or % n = 
181
Female M (SD) or % n = 
121
p
Drug Use Characteristics
Years of Primary Stimulant Use 11.14 (9.3) 13.42 (10.9) 9.14 (7.1) 0.012
Days of Cocaine Use (TLFB)a 9.00 8.00 11.00 0.002
Days of Methamphetamine Use (TLFB)b 12.00 9.50 20.00 0.006
Drug Use Diagnoses (CIDI)
Stimulant Use Disorders (%) 0.001
    Cocaine only 58.80 65.75 48.33
    Cocaine and other stimulant 30.56 28.18 34.17
    Other stimulant (not cocaine) 10.63 6.08 17.50
Alcohol Dependence (%) 50.33 57.46 39.67 0.002
Marijuana Dependence (%) 31.89 36.46 25.00 0.037
Drug Use Problems (ASI-Lite)
Alcohol 0.21 (0.2) 0.26 (0.3) 0.13 (0.2) < 0.001
Drugs 0.17 (0.1) 0.16 (0.1) 0.17 (0.1) 0.454
Employment 0.71 (0.3) 0.67 (0.3) 0.76 (0.3) 0.006
Family/Social 0.22 (0.2) 0.20 (0.2) 0.25 (0.2) 0.046
Legal 0.14 (0.2) 0.13 (0.2) 0.15 (0.2) 0.441
Medical 0.16 (0.3) 0.15 (0.3) 0.18 (0.3) 0.373
Psychiatric 0.27 (0.2) 0.22 (0.2) 0.34 (0.2) < 0.001
Nicotine Dependence Intensity (FTND)
3.45 (2.1) 3.76 (2.2) 3.02 (1.8) 0.011
Comorbid Psychiatric Diagnoses (MINI)
Major Depressive Episode (%) 22.85 19.34 28.10 0.076
Dysthymia (%) 9.44 11.64 5.75 0.137
Manic Episode (%) 4.97 2.76 8.26 0.031
Post-traumatic Stress Disorder (%) 9.60 8.29 11.57 0.343
Panic Disorder (%) 6.02 3.31 10.17 0.015
Social Phobia (%) 10.93 10.50 11.57 0.770
Obsessive Compulsive Disorder (%) 5.96 3.31 9.92 0.018
Stimulant Abstinence Severity
SSSA Score 11.77 (11.5) 10.44 (11.1) 13.78 (11.9) 0.013
Notes: TLFB = Timeline Followback; CIDI = Composite International Diagnostic Interview; ASI = Addiction Severity Index; FTND = Fagerstrom 
Test for Nicotine Dependence; MINI = Mini International Neuropsychiatric Interview; SSSA = Stimulant Selective Severity Assessment;
a
Median days of use computed for those who used cocaine in the 30 days prior to residential treatment program (RTP) entry (Men n = 157 and 
Women n = 82); and
b
Median days of use computed for those who used methamphetamine in the 30 days prior to RTP entry (Men n = 38 and Women n = 43).
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Table 2
Regression Analysis for Gender and other Variables Predicting Stimulant Abstinence Symptom Severity
B SE p
Gender 2.710 1.5 0.071
Age 0.014 0.1 0.847
High School or more Education 0.101 0.3 0.766
Employed 0.682 1.5 0.642
African American −4.651 1.6 0.005
Hispanic −2.994 2.3 0.202
Years of Primary Stimulant Use −0.020 0.1 0.820
Days of Cocaine Use −0.047 0.1 0.553
Days of Methamphetamine Use −0.046 0.1 0.647
Alcohol Dependence 2.155 1.4 0.119
Marijuana Dependence 1.015 1.5 0.485
Nicotine Dependence Intensity 0.519 1.5 0.722
Manic Episode 3.450 3.2 0.288
Panic Disorder 5.636 3.2 0.076
Obsessive Compulsive Disorder (OCD) 4.545 2.9 0.119
Notes. A follow-up analysis, showed that gender (B=3.23, SE=1.5, p=.031) was associated with abstinence symptom severity after two variables 
were removed from the model, i.e., 1) panic disorder and 2) OCD.
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